AlloSource Announces Two Innovative Bone Fiber Allografts
CENTENNIAL, Colo., June 13, 2016 /PRNewswire-USNewswire/ -- AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced the launch of two new innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and the AlloFuse® Fiber Boat, for use in a variety of spine and orthopedic procedures. TheraCell, a regenerative medicine company, developed and patented the demineralized bone fiber (DBF) technology used in these products and partnered with AlloSource to implement manufacturing and establish a distribution network for the tissue.
"The fiber technology incorporated in these allografts offers surgeons new options for their patients," said Thomas Cycyota, AlloSource president and CEO. "Our partnership with TheraCell allows us to maximize the gift of tissue donation, while also providing innovative products to fulfill an unmet need for healthcare professionals and recipients."
AlloFuse Cortical Fibers and the AlloFuse Fiber Boat represent the latest additions to the AlloFuse line of osteobiologic bone grafts, originally launched in 2009. These new DBF allografts consist of 100 percent demineralized cortical bone and offer a less costly alternative to synthetic bone void fillers. The size and geometry of the fibers have been optimized to provide exceptional handling characteristics for bone fusion procedures, primarily in spine and orthopedics.
"Collaborating with AlloSource provides a great opportunity for our DBF technology to help change lives," said Bradley Patt, Ph.D., TheraCell chairman and CEO. "We are honored to work with one of the country's leading tissue banks to advance the science of allografts."
About AlloSource
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource's products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world's largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country's most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.
About TheraCell, Inc.
TheraCell, Inc. is a regenerative medicine company developing the next generation of advanced technologies for tissue repair for both the human and veterinary markets. TheraCell has three synergistic technology platforms. The first of these is a proprietary process for making demineralized bone fibers (DBF). The second platform is an oxygenation technology. Oxygenation leads to improved tissue regeneration. The third technology platform is a point of care stem cell isolation and purification system. Founded in 2008, the firm is headquartered in Los Angeles, CA and maintains offices, laboratories and production facilities in Lowell, MA, within the M2D2 Incubator facility of the University of Massachusetts, Lowell, MA. www.theracellinc.com. DBF is a trademark of TheraCell, Inc.
Media Contact
Megan Duggan
AlloSource
720. 382. 2766
mduggan@allosource.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allosource-announces-two-innovative-bone-fiber-allografts-300283636.html
SOURCE AlloSource
